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Case presentation
A woman developed a cerebellar hemangioblastoma in
1991 at the age of 17 and von Hippel-Lindau disease
was diagnosed. She underwent ﬁve craniotomies for
recurrent hemangioblastoma. In 2001 she had a lam-
inectomy for an intramedullar hemangioblastoma at
C2-C3 level. In 2004 a renal cell carcinoma was found
and a partial nephrectomy was performed. A few
weeks after her last craniotomy in July 2005 she
developed progressive right hemisensory disturbances
and sensory ataxia. Spinal MRI showed leptomenin-
geal contrast enhancement around the entire spinal
cord (see Figure). The sensory ataxia progressed and
she got tetraparesis, most severe proximally in
her arms, especially myotome C4. Although
hemangioblastoma are not very radiosensitive, radio-
therapy was started because of the rapid clinical dete-
rioration. High-dose total neuraxis radiotherapy was
considered to toxic. It was judged that most of her
clinical complaints could be attributed to the cervical
spine. Also the MRI showed the most severe lesions at
the cervical region. Therefore she was treated from C1
to Th1 (30 · 1.8 Gy) combined with dexamethasone
(2 · 8 mg). During radiotherapy she developed also
symptoms outside the radiotherapy ﬁeld (thoracal
radiculopathy).
As the main problem in VHL is uncontrolled
angiogenesis by overexpressing VEGF and VEGF
receptors, Thalidomide (400 mg, later 600 mg) was
added. Thalidomide inhibits angiogenesis induced by
VEGF [1]. Despite the treatment she developed a total
tetraplegia and died 3 months after diagnosis as a
result of respiratory failure.
This syndrome appears to result from delayed
growth of subarachnoid tumor cells disseminated by
surgery. Hemangioblastomatosis is also seen in
hemangioblastoma patients without von Hippel-Lindau
disease and it is thought that additional genes are likely
to be the source of this malignant behaviour [2].
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